CommercialPrior AuthMedium impact
Drug Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Neurology, Psychiatry, Pain Management +2 more·Pharmacy
Effective date
Jul 1, 2026
We identified it
Jun 19, 2026
Summary
Three drug policy criteria changes take effect July 1, 2026: buprenorphine-naloxone will require new post-limit prior authorization, Twiist BCBS AR C30549-A will have new criteria, and Enspryng will require additional NMOSD clinical characteristics documentation for initial approval plus new continuation therapy requirements.
Action Required
Before July 1, 2026: Update prior authorization workflows for buprenorphine-naloxone to include post-limit PA requirements. For Enspryng prescriptions, providers must document one NMOSD clinical characteristic for initial approval and document concomitant biologic/IVIG use for therapy continuation. Update EMR templates and prior auth checklists to capture required documentation. Claims without proper authorization will be denied.